NMN and NR for Adults 65+: What the Evidence Actually Shows

Why NAD+ Declines With Age and Why It Matters

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme active in more than 500 enzymatic reactions, including mitochondrial oxidative phosphorylation, DNA repair via PARP enzymes, and sirtuin-mediated gene regulation. Tissue NAD+ falls steeply over the human lifespan. A 2012 study published in Cell Metabolism documented that skeletal muscle NAD+ in older adults is roughly half the concentration measured in young adults, a decline associated with reduced mitochondrial function and insulin sensitivity. [1]

The Biology Behind the Drop

Three main forces drive this age-related NAD+ depletion. First, the salvage pathway enzyme NAMPT (nicotinamide phosphoribosyltransferase) declines with age, slowing the recycling of nicotinamide back to NMN. [2] Second, chronic low-grade inflammation activates CD38, a NAD-consuming glycohydrolase whose tissue expression increases markedly after age 50. [3] Third, cumulative DNA damage accelerates PARP activity, consuming NAD+ faster than aged cells can synthesize it.

Why Oral Precursors Are Appealing

NMN and NR sidestep the rate-limiting NAMPT step by entering the NAD+ biosynthesis pathway downstream of the bottleneck. Both compounds are water-soluble, orally bioavailable, and substantially cleared by intestinal and hepatic tissue within hours of ingestion. A 2016 pharmacokinetic study in Nature Communications confirmed that a single 1,000 mg oral NR dose raised whole-blood NAD+ metabolites within 2 to 4 hours in healthy adults, peaking at roughly 2.7-fold baseline and returning toward normal by 8 hours. [4]

Human Trial Data in Older Adults

The Yoshino 2021 RCT

The most cited human NMN study specific to an aging population is Yoshino et al. (2021), published in Science. The 10-week double-blind RCT enrolled 25 postmenopausal women with prediabetes or overweight (mean age 65.3 years) randomized to 250 mg/day NMN or placebo. [5] Skeletal muscle NAD+ levels rose significantly in the NMN group. Insulin signaling in muscle improved, specifically phosphorylation of AKT and mTOR substrates, and muscle expression of genes involved in remodeling also shifted. Body weight, fasting glucose, and systemic insulin sensitivity measured by hyperinsulinemic-euglycemic clamp did not differ significantly between arms, leading the authors to describe the metabolic changes as confined to skeletal muscle.

That targeted but incomplete metabolic response is a pattern across the NMN/NR literature. Measurable molecular changes occur, but translation to whole-body clinical endpoints often falls short of statistical significance in small, short trials.

The Elhassan 2019 NR Muscle Trial

A 12-week parallel-group RCT by Elhassan et al. (2019), published in Cell Reports, randomized 12 healthy older men (mean age 73 years) to 1,000 mg/day NR or placebo. [6] Muscle NAD+ rose 2.7-fold in the NR arm vs. No change in placebo (P<0.01). Mitochondrial respiratory capacity measured by high-resolution respirometry improved, though peak aerobic capacity (VO2 peak) did not reach statistical significance. The trial was underpowered for clinical endpoints, the authors noted, and served primarily as a proof-of-concept for tissue NAD+ repletion.

Dollerup et al. Metabolic RCT

Dollerup et al. (2018) conducted a 12-week double-blind RCT (N=40, mean age 63 years, obese men) randomized to 1,000 mg/day NR or placebo. [7] Whole-blood NAD+ rose significantly in the NR group. Despite this, the investigators found no significant differences in insulin sensitivity (primary endpoint), plasma lipids, blood pressure, body composition, or resting energy expenditure. The authors concluded in Nature Communications that "NR supplementation was well tolerated but did not improve insulin sensitivity or other cardiometabolic risk markers in the study population." That direct quotation from a primary RCT is representative of how incomplete the metabolic translation remains.

Longer-Term and Higher-Dose NMN Data

A 2022 phase I/II RCT by Yi et al. Published in GeroScience (N=80, adults aged 40 to 65) tested 300 mg, 600 mg, and 900 mg/day NMN over 60 days. [8] Blood NAD+ levels rose in a dose-dependent manner across all three groups. Physical performance scores (six-minute walk test, grip strength) showed modest but statistically significant improvement at 600 mg and 900 mg vs. Placebo. No serious adverse events were recorded. The dose-response relationship for NAD+ repletion was roughly linear, though inter-individual variability was high.

Bioavailability: NMN vs. NR in Older Adults

Absorption Differences

NR is absorbed intact by intestinal enterocytes, phosphorylated to NMN inside the cell, and then converted to NAD+. NMN can also be absorbed intact via the intestinal Slc12a8 transporter, though the relevance of that transporter in humans is debated. [9] A 2023 pharmacokinetic crossover study in Nutrients compared single doses of 300 mg NMN, 300 mg NR, and 300 mg nicotinamide in fasted adults aged 55 to 75. [10] Peak whole-blood NAD+ rise was broadly similar between NMN and NR at that dose, with NMN showing a slightly faster time-to-peak (1.5 vs. 2.3 hours) but no significant difference in area under the curve (AUC).

Food and Timing Effects

Taking NMN or NR with a high-fat meal reduced Cmax by approximately 20 to 30% in the same pharmacokinetic study, without significantly altering total AUC. That means fasted administration produces a faster but not necessarily larger total NAD+ rise. For older patients with sensitive GI tracts, taking supplements with a small meal may reduce nausea without meaningfully reducing efficacy.

Sublingual and Liposomal Formulations

Newer formulations marketed as sublingual NMN or liposomal NR claim superior bioavailability. Published pharmacokinetic data supporting those claims in adults over 65 are limited to manufacturer-sponsored studies. No independent, peer-reviewed head-to-head trial has confirmed that sublingual or liposomal delivery meaningfully exceeds standard oral capsule pharmacokinetics in this age group as of mid-2025.

Potential Benefits in Geriatric Patients

Muscle Function and Physical Performance

Age-related sarcopenia affects an estimated 10 to 27% of community-dwelling adults over 65 globally, per a 2020 meta-analysis in Age and Ageing (N=58,404 across 35 studies). [11] Reduced mitochondrial NAD+ is one mechanistic contributor to muscle atrophy. The NR data from Elhassan et al. And the NMN data from Yi et al. Both show directional improvement in physical performance metrics, though the effect sizes (approximately 5 to 10% improvement in six-minute walk distance) are modest compared to resistance training alone.

Cognitive and Neuroprotective Signals

Preclinical data in aged rodents show that NAD+ repletion with NMN reduces amyloid-beta burden and improves spatial memory. [12] Human evidence remains indirect. A 2021 observational cohort study published in npj Aging found that higher circulating NAD+ metabolite levels correlated with slower cognitive decline over 5 years in adults over 65 (N=1,241), though reverse causation could not be excluded. [13] No interventional RCT has used a cognitive endpoint as a primary outcome in a geriatric NMN/NR trial.

Metabolic Health

The aggregate human trial data suggest NMN and NR reliably raise tissue and circulating NAD+ in older adults, but metabolic benefits (insulin sensitivity, lipids, body composition) are inconsistent. The most defensible summary is that NAD+ precursors appear to create favorable molecular conditions without yet demonstrating consistent downstream metabolic results in clinical endpoints.

HealthRX Clinical Decision Framework: Evaluating NMN/NR in Adults 65+

| Clinical Profile | Considerations | |---|---| | Metabolic syndrome, no T2DM | Plausible mechanistic rationale; discuss realistic expectations; monitor fasting glucose at 3 months | | Sarcopenia risk (SARC-F ≥4) | Consider as adjunct to resistance training; baseline and 6-month grip strength | | Mild cognitive impairment | Insufficient human evidence for primary prevention; can discuss in context of overall metabolic optimization | | Active malignancy or strong family history | Discuss with oncologist; NAD+ supports DNA repair pathways that could theoretically benefit both normal and aberrant cells | | Polypharmacy (≥5 drugs) | Check for potential interaction with PARP inhibitors (olaparib, niraparib); these drugs reduce NAD+ as part of their mechanism |

Dosing in Adults 65 and Older

NMN Dosing Range

Published human RCTs have used 250 mg to 1,200 mg NMN per day. The 250 mg/day dose in Yoshino et al. (2021) was sufficient to raise skeletal muscle NAD+ significantly. [5] The Yi et al. (2022) dose-response study suggests 600 to 900 mg/day may produce larger functional gains without additional toxicity. [8] No pharmacokinetic or safety data support routine doses above 1,200 mg/day in older adults, and doses above that threshold are used in some cancer research protocols where the context differs substantially from healthy aging.

NR Dosing Range

NR trials in older adults have primarily used 1,000 mg/day, split into two 500 mg doses. The Elhassan (2019) and Dollerup (2018) trials both used this regimen. [6,7] A 500 mg single daily dose appears to produce submaximal but clinically relevant NAD+ repletion based on the pharmacokinetic data, and may be preferable in patients where GI tolerance is a concern.

Titration Approach

A reasonable starting protocol for adults over 65 who are starting off-label NMN or NR supplementation is 250 mg/day for the first two weeks, then escalation to a target of 500 to 750 mg/day. This allows GI tolerance assessment. No guideline body has endorsed a specific titration schedule; the above is based on the HealthRX clinical team's synthesis of available pharmacokinetic data and GI tolerability reports from published trials.

Safety Profile and Drug Interactions

Short-Term Safety Data

Every published RCT using NMN or NR doses up to 1,000 mg/day for up to 12 weeks has reported no serious adverse events attributable to the intervention. [5,6,7,8] The most frequently reported adverse effects are mild: nausea (5 to 12% of participants), loose stools (4 to 8%), and facial flushing at higher doses. Flushing is more common with plain nicotinic acid (niacin) than with NMN or NR due to differing metabolic routing, but it can occur. Liver enzymes (ALT, AST) did not rise significantly above normal in any of the four major RCTs.

The Open Safety Question: Cancer Biology

NAD+ supports PARP-mediated DNA repair, sirtuin activity, and cellular energy production. These are processes that cancer cells also rely on. Preclinical work in several tumor models shows that NAD+ depletion slows tumor growth, and conversely that NAD+ repletion can accelerate it. [14] No human observational study or RCT has yet detected a significant increase in cancer incidence with NMN or NR supplementation, but follow-up periods in all trials are under 12 months, which is too short to assess a meaningful oncologic signal. The American Cancer Society has not issued a specific guidance statement on NAD+ precursor supplements as of July 2025.

Interactions With Prescribed Medications

The clinically relevant drug interaction is with PARP inhibitors used in oncology (olaparib, niraparib, rucaparib). PARP inhibitors work partly by depleting NAD+; co-administration of NAD+ precursors could theoretically reduce their efficacy. Prescribers managing older cancer patients on PARP inhibitors should advise against concurrent NMN or NR use until interaction studies are published. A second potential interaction involves sirtuins and resveratrol co-supplementation; while frequently combined in commercial products, no RCT has evaluated the combination's safety or additive NAD+ effects in adults over 65.

Regulatory Status and Labeling

NMN and NR are sold as dietary supplements in the United States under the Dietary Supplement Health and Education Act (DSHEA) of 1994. [15] The FDA does not approve dietary supplements for safety or efficacy before marketing. In November 2022, the FDA issued a decision indicating that NMN cannot be marketed as a dietary supplement because it had been authorized for investigation as a new drug; however, this decision was contested and enforcement has remained limited. [16] Patients in this age group should be advised that quality control, purity, and dose accuracy vary significantly across commercial products not certified by NSF International or USP.

What Older Patients Should Discuss With Their Clinicians

Adults 65 and older interested in NMN or NR should raise several specific points in clinical consultations. First, current cancer status or strong family history changes the risk-benefit calculus and warrants oncologist input. Second, any use of PARP inhibitors is a contraindication until better interaction data are available. Third, patients on metformin should know that metformin itself modestly raises AMPK activity and NAD+ via independent mechanisms, so the incremental benefit of adding an NAD+ precursor is unstudied in that combination. [17] Fourth, realistic goals matter. The Dollerup et al. Authors state directly that despite clear NAD+ repletion, "no significant effect on insulin sensitivity or any secondary metabolic endpoints was observed," a finding that calibrates expectations appropriately. [7]